Search clinical trials for: 800 μg AZD7594 once daily

Total 843 results

AstraZeneca

Completed

A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7594 Inhaled Formulation in Healthy Japanese Men

Asthma | Chronic Obstructive Pulmonary Disease COPD

United States
AstraZeneca

Completed

A Multiple Dosing (14 Days) Study to Assess Efficacy and Safety of Three Dose Levels of AZD7594, Given Once Daily by Inhalation, in Patients With Mild to Moderate Asthma

Asthma | Efficacy | Safety

Germany, Bulgaria
AstraZeneca
Parexel

Completed

A Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD7594 Administered Once Daily by Inhalation in Asthmatic Subjects

Asthma

United States, Germany, South Africa, Ukraine, Japan, Hungary, Poland, Bulgaria
AstraZeneca

Completed

A Study to Assess the Bioavailability and to Compare the Pharmacokinetics of AZD7594 Inhaled Via Monodose Inhaler and Multiple-dose Dry Powder Inhalers (DPI) or Pressurized Metered-dose Inhaler (pMDI) in Healthy Male Subjects

Asthma | Chronic Obstructive Pulmonary Disease (COPD)

United States
Anhui Palo Alto Pharmaceuticals, Inc.

Recruiting

Safety and Efficacy Study of PA9159 Nasal Spray for the Treatment of Seasonal Allergic Rhinitis

Allergic Rhinitis

China
Alebund Pty Ltd

Completed

A Safety, Tolerability, and Pharmacokinetics Study of AP303 in Healthy Subjects

Healthy Subjects

Australia
Basilea Pharmaceutica

Completed

Derazantinib and Atezolizumab in Patients With Urothelial Cancer (FIDES-02)

Urothelial Carcinoma

United Kingdom, Korea, Republic of, Italy, Canada, France, Spain, Germany, United States, Hungary, Australia, Poland, Switzerland, Czechia, Austria
AstraZeneca

Completed

Safety and Tolerability Study of MEDI0382 in Japanese Preobese or Obese Subjects With Type 2 Diabetes

Type 2 Diabetes

Japan
Rennes University Hospital

Completed

Fludrocortisone in Healthy Volunteers (AFLUCO4) (AFLUCO4)

Healthy Volunteers

France
AstraZeneca
Quotient Sciences

Completed

Absolute Bioavailability and ADME Study of Savolitinib in Healthy Male Subjects

Cancer

United Kingdom
Judit Pich Martínez

Completed

A Phase I, Open Label Dose Escalation Study to Evaluate Safety of iHIVARNA-01 in Chronically HIV-infected Patients Under Stable Combined Antiretroviral Therapy

HIV-infection

Spain
Boehringer Ingelheim

Completed

This Study is Done in Patients With Plaque Psoriasis and Tests How Well They Tolerate BI 730357 and How Effective it is

Psoriasis

United States, Canada, Germany
Maruho Co., Ltd.

Completed

Open-label Study of ASP2151 in Herpes Simplex Patients

Herpes Simplex

Japan
Johnson & Johnson Pharmaceutical Research & Development...

Terminated

An Efficacy and Safety Study of JNJ-26113100 in the Treatment of Adult Atopic Dermatitis

Atopic Dermatitis

United States
MerLion Pharmaceuticals GmbH

Completed

Finafloxacin for the Treatment of cUTI and/or Acute Pyelonephritis

Urinary Tract Infections | Acute Pyelonephritis

Germany
GlaxoSmithKline

Completed

Safety and Immunogenicity Study of a Booster Dose of the Investigational CV0501 mRNA COVID-19 Vaccine in Adults at Least 18 Years Old

COVID-19 | SARS-CoV-2

Australia, United States, Philippines
Alebund Pharmaceuticals

Not yet recruiting

A Study to Evaluate the Safety, Tolerability, PK and PD of AP303 in Healthy Chinese Participants

Healthy Subjects
University of Alabama at Birmingham
Novartis

Terminated

Effect of the Direct Renin Inhibitor Aliskiren on Endothelial Function and Arterial Stiffness in Diabetic Subjects

Hypertension | Diabetes | Pre-hypertension

United States
Bial - Portela C S.A.

Completed

Efficacy, Safety, and Tolerability of Eslicarbazepine Acetate in the Recurrence Prevention of Bipolar I Disorder

Bipolar I Disorder
Eli Lilly and Company

Completed

Enzastaurin Before and Concomitant With Radiation, Followed by Enzastaurin in Participants With Newly Diagnosed Glioblastoma

Glioblastoma Multiforme

Germany
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Pharmacokinetic and Pharmacodynamic Study of Once-Daily and Twice-Daily Dosing With Canagliflozin in Healthy Adult Volunteers

Healthy
Otsuka Pharmaceutical Co., Ltd.

Completed

A Phase 2 Trial of OPC-64005 for Major Depressive Disorder

Major Depressive Disorder

Japan
ViiV Healthcare
GlaxoSmithKline

Terminated

Dose-finding Study of GSK2248761 in Antiretroviral Therapy-experienced Subjects With NNRTI-resistant HIV Infection (SONNET)

Infection, Human Immunodeficiency Virus

United States, Canada, Italy, Belgium, Romania
Kowa Company, Ltd.

Recruiting

A Phase III Confirmatory Study of K-877 (Pemafibrate) in Patients With Hypercholesterolemia and Statin Intolerance

Hypercholesterolemia

Japan
AstraZeneca

Completed

Efficacy and Safety of Aclidinium Bromide at Two Dose Levels Versus Placebo Administered in Chronic Obstructive Pulmonary Disease (COPD) Patients

Chronic Obstructive Pulmonary Disease (COPD)

Germany, Czech Republic, France, Hungary, Italy, Peru, Poland, Russian Federation, South Africa, Spain, Ukraine
GlaxoSmithKline

Completed

A 52-Week, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety and Tolerability of GSK573719/GW642444 and GSK573719 in Subjects With Chronic Obstructive Pulmonary Disease (COPD) (COPD nDPI)

Pulmonary Disease, Chronic Obstructive

United States, Russian Federation, Chile, South Africa, Romania, Slovakia
Inflazyme Pharmaceuticals Ltd

Completed

Control of Asthma Patients Symptomatic on Inhaled Corticosteroids

Asthma

United States
Mylan Pharmaceuticals Inc

Completed

Fasting Study of Levothyroxine Sodium Tablets 300 μg to Synthroid® Tablets 300 μg

Healthy

United States
Mylan Pharmaceuticals Inc

Completed

Fasting Study of Levothyroxine Sodium Tablets 300 μg to Levothroid® Tablets 300 μg

Healthy

United States
GlaxoSmithKline

Completed

Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of GSK2292767 in Healthy Participants Who Smoke Cigarettes

Asthma

United Kingdom
Chang Gung Memorial Hospital
National Science Council, Taiwan

Completed

Dosage Determination Trial for Indigo Naturalis Extract in Oil Ointment

Psoriasis Vulgaris

Taiwan
GlaxoSmithKline

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Combination of GSK573719 and GW642444 in Subjects With COPD

Pulmonary Disease, Chronic Obstructive

United States
Dr. Reddy's Laboratories Limited

Completed

A Study to Evaluate Two Concentrations of DFD-07 Cream, in Subjects With Actinic Keratosis (AK) of the Face and/or Scalp Over a 12-week Treatment Period

Actinic Keratosis (AK)

United States
Tibotec Pharmaceuticals, Ireland

Completed

A Study to Determine the Antiviral Activity of TMC310911 When Administered With Ritonavir in Treatment-Naive Human Immunodeficiency Virus - Type 1 (HIV-1) Infected Patients

Human Immunodeficiency Virus Type 1

Germany
ViiV Healthcare
GlaxoSmithKline

Terminated

Dose-finding Study of GSK2248761 in Antiretroviral Therapy-Naive Subjects (SIGNET) (SIGNET)

Infection, Human Immunodeficiency Virus

Spain, France, Germany
GlaxoSmithKline

Completed

A Study of GSK573719 in Healthy Japanese Male Subjects

Pulmonary Disease, Chronic Obstructive

Japan
Bausch Health Americas, Inc.

Completed

Rifaximin Soluble Solid Dispersion (SSD) Tablets Plus Lactulose for the Treatment of Overt Hepatic Encephalopathy (OHE) (OHE)

Overt Hepatic Encephalopathy

United States
Egyptian Liver Hospital
Wadi El Nil Hospital

Completed

Randomized, Open-Label, Study to Evaluate the Safety and Efficacy of Sofosbuvir Tablet Plus Ribavirin Tablet (Part A) Versus Single Dose (2 Tablets) of EHCV Containing Sofosbuvir, Ribavirin, and Natural Anti-hemolytic (B) in Egyptian Adults With Chronic Genotype 4 HCV Infection

Hepatitis c

Egypt
Pfizer

Terminated

Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients at Early Stage of the Disease

Parkinson Disease

United States, France, Israel, Germany
Spectrum Pharmaceuticals, Inc

Terminated

Study of Poziotinib in Japanese Patients With NSCLC

NSCLC

Japan
Kowa Company, Ltd.

Completed

A Phase III Confirmatory Study of K-877 Extended Release Tablet

Dyslipidemias

Japan
Unity Health Toronto

Completed

Screening Frequency Trial to Identify Weaning Candidates (RELEASE)

Critically Ill

Canada
St Stephens Aids Trust
University of Turin, Italy; University of Liverpool

Completed

Boceprevir and Ucalm (St John&Apos;s Wort)

Hepatitis C

United Kingdom
Anhui Palo Alto Pharmaceuticals, Inc.

Completed

Safety, Tolerability, and Pharmacokinetics of PA9159 Nasal Spray in Healthy Adult Subjects

Allergic Rhinitis

China
Case Western Reserve University
National Institute of Nursing Research (NINR); MetroHealth Medical Center

Completed

Dose of Early Therapeutic Mobility: Does Type or Frequency Matter? (ETM)

Critical Illness

United States
Unity Health Toronto

Completed

Screening Elderly Patients for Weaning

Critically Ill

Canada
Kowa Company, Ltd.

Completed

A Phase III Long Term Study of K-877 Extended Release Tablet

Dyslipidemias

Japan
Tris Pharma, Inc.
Forest Laboratories

Completed

A Clinical Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of Cebranopadol

Pharmacokinetic

United States
National Cancer Institute, Egypt

Unknown

Whole Breast Irradiation vs Twice Daily vs. Once Daily Accelerated Partial Breast Irradiation

Breast Cancer | Radiation Toxicity

Egypt
OBI Pharma, Inc

Recruiting

To Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (EGFR)

Non-small Cell Lung Cancer

Taiwan

3

Subscribe